Novartis reports detailed PFS data for Kisqali to treat breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) reported additional data from the Phase III MONALEESA-7 trial to treat breast cancer showing that first-line treatment with Kisqali ribociclib (LEE011) in combination with goserelin and either tamoxifen or an aromatase

Read the full 354 word article

User Sign In